The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
| Title: | The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers. |
|---|---|
| Authors: | Bancroft EK; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK.; Page EC; Oncogenetics Team, Institute of Cancer Research, London, UK.; Brook MN; Oncogenetics Team, Institute of Cancer Research, London, UK.; Pope J; Oncogenetics Team, Institute of Cancer Research, London, UK.; Thomas S; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Myhill K; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Helfand BT; Division of Urology, John and Carol Walter Center for Urological Health, NorthShore University HealthSystem, Evanston, IL, USA.; Talaty P; Division of Urology, John and Carol Walter Center for Urological Health, NorthShore University HealthSystem, Evanston, IL, USA.; Ong KR; West Midlands Regional Clinical Genetics Service, Birmingham Women's Hospital, Birmingham, UK.; Douglas E; West Midlands Regional Clinical Genetics Service, Birmingham Women's Hospital, Birmingham, UK.; Cook J; Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, UK.; Rosario DJ; Royal Hallamshire Hospital, Sheffield, UK.; Salinas M; Hereditary Cancer Program, ICO (Catalan Institute of Oncology), Barcelona, Spain.; Buys SS; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.; Anson J; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.; Davidson R; West of Scotland Genetic Service, Queen Elizabeth University Hospital, Glasgow, UK.; Longmuir M; West of Scotland Genetic Service, Queen Elizabeth University Hospital, Glasgow, UK.; Side L; Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.; Eccles DM; Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.; The University of Southampton Medical School, Southampton, UK.; Tischkowitz M; East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Trust, Cambridge, UK.; Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.; Taylor A; East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Trust, Cambridge, UK.; Cruellas M; Hereditary Cancer Genetics Group, Medical Oncology Department, Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Ballestero EP; Hereditary Cancer Genetics Group, Medical Oncology Department, Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Cleaver R; Peninsula Clinical Genetics Service, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.; Varughese M; Peninsula Clinical Genetics Service, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.; Barwell J; University of Leicester, Leicester, UK.; University Hospitals Leicester, Leicester, UK.; LeButt M; University Hospitals Leicester, Leicester, UK.; Greenhalgh L; Liverpool Centre for Genomic Medicine, Liverpool Women's NHS Foundation Trust, Liverpool, UK.; Hart R; Liverpool Centre for Genomic Medicine, Liverpool Women's NHS Foundation Trust, Liverpool, UK.; Azzabi A; Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.; Jobson I; Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.; Cogley L; Peninsular Genetics, Derriford Hospital, Plymouth, UK.; Evans DG; Genomic Medicine, Manchester Academic Health Sciences Centre, Manchester University NHS Foundation Trust, Manchester, UK.; Rothwell J; Genomic Medicine, Manchester Academic Health Sciences Centre, Manchester University NHS Foundation Trust, Manchester, UK.; Taylor N; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Hogben M; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Saya S; Oncogenetics Team, Institute of Cancer Research, London, UK.; The University of Melbourne, Melbourne, Australia.; Eeles RA; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK.; Aaronson NK; Netherlands Cancer Institute, Amsterdam, Netherlands. |
| Corporate Authors: | IMPACT Study Steering Committee; IMPACT Collaborators |
| Source: | BJU international [BJU Int] 2024 Sep; Vol. 134 (3), pp. 484-500. Date of Electronic Publication: 2024 Jun 05. |
| Publication Type: | Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-410X (Electronic) Linking ISSN: 14644096 NLM ISO Abbreviation: BJU Int Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Oxford, UK : Blackwell Science, c1999- |
| MeSH Terms: | Prostatic Neoplasms*/psychology ; Prostatic Neoplasms*/genetics ; Prostatic Neoplasms*/diagnosis ; Genetic Predisposition to Disease*/psychology ; Early Detection of Cancer*/psychology; Anxiety/etiology ; Humans ; Male ; Middle Aged ; Aged ; Quality of Life ; Genes, BRCA1 ; Surveys and Questionnaires ; Genes, BRCA2 ; Heterozygote ; Longitudinal Studies |
| Abstract: | Objectives: To report the long-term outcomes from a longitudinal psychosocial study that forms part of the 'Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls' (IMPACT) study. The IMPACT study is a multi-national study of targeted prostate cancer (PrCa) screening in individuals with a known germline pathogenic variant (GPV) in either the BReast CAncer gene 1 (BRCA1) or the BReast CAncer gene 2 (BRCA2).; Subjects and Methods: Participants enrolled in the IMPACT study were invited to complete a psychosocial questionnaire prior to each annual screening visit for a minimum of 5 years. The questionnaire included questions on sociodemographics and the following measures: Hospital Anxiety and Depression Scale, Impact of Event Scale, 36-item Short-Form Health Survey, Memorial Anxiety Scale for PrCa, Cancer Worry Scale, risk perception and knowledge.; Results: A total of 760 participants completed questionnaires: 207 participants with GPV in BRCA1, 265 with GPV in BRCA2 and 288 controls (non-carriers from families with a known GPV). We found no evidence of clinically concerning levels of general or cancer-specific distress or poor health-related quality of life in the cohort as a whole. Individuals in the control group had significantly less worry about PrCa compared with the carriers; however, all mean scores were low and within reported general population norms, where available. BRCA2 carriers with previously high prostate-specific antigen (PSA) levels experience a small but significant increase in PrCa anxiety (P = 0.01) and PSA-specific anxiety (P |
| References: | Cancer Research UK. Prostate cancer statistics. Available at: https://www.cancerresearchuk.org/health‐professional/cancer‐statistics/statistics‐by‐cancer‐type/prostate‐cancer. Accessed January 2024.; Kote‐Jarai Z, Leongamornlert D, Saunders E et al. BRCA2 is a moderate penetrance gene contributing to young‐onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011; 105: 1230–1234.; Leongamornlert D, Mahmud N, Tymrakiewicz M et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 2012; 106: 1697–1701.; Castro E, Goh C, Leongamornlert D et al. Effect of BRCA mutations on metastatic relapse and cause‐specific survival after radical treatment for localised prostate cancer. Eur Urol 2015; 68: 186–193.; Page EC, Bancroft EK, Brook MN et al. Interim results from the IMPACT study: evidence for prostate‐specific antigen screening in BRCA2 mutation carriers. Eur Urol 2019; 76: 831–842.; Andriole GL, Crawford ED, Grubb RL 3rd et al. Mortality results from a randomized prostate‐cancer screening trial. N Engl J Med 2009; 360: 1310–1319.; Pinsky PF, Prorok PC, Yu K et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years. Cancer 2017; 123: 592–599.; Donovan JL, Hamdy FC, Lane JA et al. Patient‐reported outcomes 12 years after localized prostate cancer treatment. NEJM Evid 2023; 2: EVIDoa2300018.; Brindle LA, Oliver SE, Dedman D et al. Measuring the psychosocial impact of population‐based prostate‐specific antigen testing for prostate cancer in the UK. BJU Int 2006; 98: 777–782.; Bancroft EK, Castro E, Bancroft GA et al. The psychological impact of undergoing genetic‐risk profiling in men with a family history of prostate cancer. Psychooncology 2015; 24: 1492–1499.; Mottet N, Bellmunt J, Bolla M et al. EAU‐ESTRO‐SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618–629.; NCCN. Available at: https://www.nccn.org/guidelines/guidelines‐detail?category=2&id=1460. Accessed January 2024.; Bancroft EK, Saya S, Page EC et al. Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. BJU Int 2019; 123: 284–292.; Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–370.; Horowitz M. Stress response syndromes and their treatment. In Goldberger L, Breznitz S eds, Handbook of Stress: Theoretical and Clinical Aspects. New York, London: Collier Macmillan, 1986.; Watson M, Lloyd S, Davidson J et al. The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer. Br J Cancer 1999; 79: 868–874.; Dale W, Hemmerich J, Meltzer D. Extending the validity of the memorial anxiety scale for prostate cancer (MAX‐PC) at the time of prostate biopsy in a racially‐mixed population. Psychooncology 2007; 16: 493–498.; Jenkinson C, Stewart‐Brown S, Petersen S, Paice C. Assessment of the SF‐36 version 2 in the United Kingdom. J Epidemiol Community Health 1999; 53: 46–50.; Maruish ME, DeRosa MA. A Guide to the Integration of Certified Short Form Survey Scoring and Data Quality Evaluation Capabilities. Lincoln, RI: QualityMetric Incorporated, 2009.; Ronningas U, Fransson P, Holm M, Wennman‐Larsen A. Prostate‐specific antigen (PSA) and distress: ‐ a cross‐sectional nationwide survey in men with prostate cancer in Sweden. BMC Urol 2019; 19: 66.; Vasarainen H, Malmi H, Maattanen L et al. Effects of prostate cancer screening on health‐related quality of life: results of the Finnish arm of the European randomized screening trial (ERSPC). Acta Oncol 2013; 52: 1615–1621.; Macefield RC, Lane JA, Metcalfe C et al. Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy? Eur J Cancer 2009; 45: 2569–2573.; Carlsson S, Aus G, Wessman C, Hugosson J. Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) ‐ results from a prospective, population‐based, randomised study. Eur J Cancer 2007; 43: 2109–2116.; Goodwin B, Anderson L, Collins K et al. Anticipatory anxiety and participation in cancer screening. A systematic review. Psychooncology 2023; 32: 1773–1786.; Long NN, Lau MPXL, Lee ARYB, Yam NE, Koh NYK, Ho CSH. Motivational interviewing to improve the uptake of colorectal cancer screening: a systematic review and meta‐analysis. Front Med (Lausanne) 2022; 9: 889124.; Taylor KL, Shelby R, Gelmann E, McGuire C. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. J Natl Cancer Inst 2004; 96: 1083–1094.; Ware JE Jr, Sherbourne CD. The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–483.; Moynihan C, Bancroft EK, Mitra A et al. Ambiguity in a masculine world: being a BRCA1/2 mutation carrier and a man with prostate cancer. Psychooncology 2017; 26: 1987–1993.; Bratt O, Damber JE, Emanuelsson M et al. Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer. Eur J Cancer 2000; 36: 235–241. |
| Grant Information: | C5047/A21332 Institute of Cancer Research UK; C5047/A13232 Institute of Cancer Research UK; C5047/A17528 Institute of Cancer Research UK; Ronald and Rita McAulay Foundation; Peacock Charitable Trust; NIHR Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden Foundation NHS Trust; Oxford Biomedical Research Centre Program; NIHR203312 NIHR Cambridge Biomedical Research Centre; IS-BRC-1215-20007 Manchester University Foundation Trust; Cambridge Clinical Research Centre |
| Contributed Indexing: | Investigator: Z Kote-Jarai; A Ardern-Jones; C Bangma; E Castro; D Dearnaley; J Eyfjord; A Falconer; C Foster; H Grönberg; FC Hamdy; ÓÞ Jóhannsson; V Khoo; H Lilja; G Lindeman; J Lubinski; L Maehle; A Millner; C Mikropoulos; A Mitra; C Moynihan; J Offman; G Rennert; M Suri; P Wilson; J Melia; G Mitchell; S Moss; F Schroder; D Easton; S Peock; P Sibley; R Sharifi; P James; S Shanley; K Richardson; J McKinley; L Petelin; M Murphy; L Mascarenhas; K Reeve; D Murphy; J Lam; M Chong; G Suthers; N Poplawski; R Ward; K Tucker; L Andrews; R Williams; J Duffy; R Millard; T Jarvis; P Stricker; J Kirk; M Bowman; M Patel; M Harris; S O'Connell; C Hunt; C Smyth; M Frydenberg; C Morton; K Shackleton; R Susman; J McGaughran; M Boon; S Townshend; L Schofield; N Pachter; A Spigelman; M Gleeson; R Scott; D Amor; J Burke; B Patterson; P Swindle; W Foulkes; Z Rezoug; L Feng; T Boshari; N Taherian; A Aprikian; M Jeanjean; TD Jensen; K Rønlund; P Osther; MK Tondering; AM Gerdes; R Schmutzler; K Rhiem; K Luedtke-Heckenkamp; P Wihler; N Ochsendorf; K Fiddike; N Herold; K Kast; S Zastrow; C Griebsch; O Johannsson; V Stefansdottir; V Murthy; R Sarin; P Kowtal; D Gallagher; R Bambury; M Farrell; FGI Kiernan; M Smith; S Warren; A Cahill; V Murphy; C Fleming; E Morrin; R Chen-Shtoyerman; A Basevitch; D Leibovici; E Melzer; SJ Ben-Yehoshua; E Friedman; N Nicolai; P Radice; R Valdagni; T Magnani; F Zollo; M Catanzaro; M Sorrentino; S Gay; M Vitellaro; HM Tan; SY Yoon; SH Teo; MK Thong; H Vasen; C van Asperen; J Ringelberg-Borsboom; H van Randeraad; W van Zelst-Stams; MGEM Ausems; RB Van der Luijt; T van Os; MWG Ruijs; MA Adank; RA Oldenburg; JC Oosterwijk; L Mæhle; EM Grindedal; E Hanslien; K Axcrona; C Cybulski; D Wokolorczyk; M Teixeira; S Maia; M Cardoso; A Peixoto; R Henrique; J Oliveira; N Gonçalves; L Araújo; JP Souto; P Nogueira; D Ilencikova; L Copakova; J Zgajnar; M Krajc; A Vrecar; G Capella; T Ramón Y Cajal; NC Verges; J Mora; J Palou; C López; D Fisas; A Gisbert; J Balmaña; N Gadea; J Morote; A Liljegren; M Hjälm-Eriksson; KJ Ekdahl; S Carlsson; A George; Z Kemp; J Wiggins; C Moss; L Verdon; N Van As; A Thompson; C Ogden; C Woodhouse; P Kumar; D Cahill; K Tricker; B Bulman; T Thomas; A Ruiz; D Ball; O Jones; C Mercer; D McBride; PCG Wise; A Pearce; V Sands; A Torokwa; V Gnanapragasam; L Walker; D Halliday; E Stobie; H Purnell; B Stayner; F Hamdy; H Chalinor; V Miller; K Saunders; H Hanson; M Manalo; D Dudakia; A Dearing; S Hodgson; G Brice; T Homfray; C Hammond; E Winchester; M Mencias; C Brewer; L Park; J Ireland; A Potter; C Renton; A Searle; K Hill; S Goodman; L Garcia; G Devlin; S Everest; M Nadolski; D Fuller; C Grey; M Hutchings; K Gupwell; M Thomas; M Bradford; S Cookson; L Adams; H Wannell; S Ashman; R Kelland; E Paez; A Henderson; F Douglas; A Donaldson; A Watford; S Tomkins; L Izatt; V Tripathi; M Weston; K Hilario; G Pichert; C Jacobs; CLM Mencias; A Kulkarni; B De Souza; C Turnbull; A Youngs; C Compton; A Brady; V Clowes; H Dorkins; F Arshad; A Melville; M Kosicka-Slawinska; C Cummings; V Kiesel; M Bartlett; K Randhawa; N Ellery; C Sequeira; S Sakuma; D Georgiou; T Adeoye; M Ahmed; A Male; J Gurasashvili; K Simon; K Rees; L Tidey; L Coulier; C Gabriel; E Quinn; N Solanky; J Davies; P Bayliss; L Patterson; S Ingram; K Armitage; A Howell; C Ward; J Catto; J Howson; J Hoffman; C Huber; M Chandrashekara; W Glover; F Islam; S Ali; L Burgess; C Chapman; T Heaton; T Cole; C Watt; A Duncan; N Bradshaw; L Snadden; J Gorrie; R Kockelbergh; S Mzazi; C Poile; A Sattar; B Kaemba; Z Sidat; N Patel; K Siguake; A Branson; A Birt; U Poultney; N Umez-Eronini; J Mom; B Wilkinson; M Davies; R O'Keefe; A Johnstone; G Roberts; A Woodward; V Sutton; Q Baker; P Cornford; NBK Treherne; J Griffiths; P Yesildag; H Gott; M Brennan; N Salvatore; S Freemantle; C Selkirk; P Hulick; W Rubinstein; C Brendler; K Kaul; D Shevrin; S Weissman; A Newlin; K Vogel; S Weiss; K O'Toole; T Conner; V Venne; R Stephenson; C Dechet; S Domchek; J Powers; B Arun; S Strom; JW Davis; Y Yamamura; E Obeid; L Bealin; L Bagden; S Montgomery; V Giri; L Gross; K Cooney; E Stoffel; L Okoth; M Asselman; HP Beerlage; W Blitz; ER Boevé; CA Bout; G Commelin; EB Cornel; RJAM Davits; JAPM de Hond; GA Dijkman; JG Fernandes; KBJ Fransis; ADH Geboers; R Gilhuis; JJP Jaspars; IJ Jong; MMGJ Jongen-Huinink; HFM Karthaus; PJM Kil; PE Kleingeld; WJ Kniestedt; BC Knipscheer; RF Kropman; MI Lampe; SI Langbein; JWHM Langeveld; JAF Leenarts; MR Leter; MTWT Lock; AHP Meier; B Meijer; GJ Molijn; PFA Mulders; N Naderi; MA Noordzij; JW Noordzij; FPPM Pernet; EPM Roos; MJ Schaaf; RJH Schaafsma; GAHJ Smits; S Smorenburg; JR Spermon; G van Andel; E van Boven; C van de Beek; IW van der Cruijsen-Koeter; HG van der Poel; OB van Vierssen Trip; PDJ Vegt; APM Verhulst; J Verlind; P Vijverberg; PA Wertheimer; BP Wijsman; JV Zambon; Keywords: BRCA1; BRCA2; genetic screening; prostate cancer; psychosocial; quality of life |
| Entry Date(s): | Date Created: 20240605 Date Completed: 20240826 Latest Revision: 20250304 |
| Update Code: | 20260130 |
| DOI: | 10.1111/bju.16432 |
| PMID: | 38839570 |
| Database: | MEDLINE |
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't